Search

Your search keyword '"Nicolini, L"' showing total 220 results

Search Constraints

Start Over You searched for: Author "Nicolini, L" Remove constraint Author: "Nicolini, L"
220 results on '"Nicolini, L"'

Search Results

1. Clinical characteristics and oncologic outcomes of bladder neuroendocrine carcinoma in a contemporary, multi-institutional cohort

2. Risk factors associated with NAFLD in people living with HIV

4. Design of a CZT Gamma-Camera for GRB and Fast Transient Follow-up: a Wide-Field-Monitor for the EDGE Mission

6. Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort

7. Weight Gain: A Possible Side Effect of All Antiretrovirals

8. Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study

10. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

11. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

12. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

13. Clinical management of imported malaria in Italy: Results from a national cross-sectional survey in 2015

14. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

15. Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19

16. Comments on 'Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C'

18. Forecast model for the evaluation of economic resources employed in the health care of patients with HIV infection

19. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA)

20. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

21. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)

22. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

23. The AGILE silicon tracker: Pre-launch and in-flight configuration

24. Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity

26. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

27. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

28. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

29. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)

30. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

31. Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients

32. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

34. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

36. Weight gain: A possible side effect of all antiretrovirals

37. Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?

38. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018

39. Introduzione

40. Apuleio, Metamorfosi, vol. I (libri I-III)

43. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

46. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

47. Effectiveness of first-generation HCV protease inhibitors: Does HIV coinfection still play a role?

50. L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV

Catalog

Books, media, physical & digital resources